Patent Term Application for REDEMPLO (plozasiran), Patent No. 11,214,801 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2026-E-1017

Patent Term Application for REDEMPLO (plozasiran), Patent No. 11,214,801

Documents

Comments

Description

OPEN

Comment Period OpensFeb 2, 2026

Type	Title	Posted	Comments	Status
Other	Letter to U. S. Patent and Trademark Office	Apr 20, 2026	--

CDER

Finnegan, Henderson, Farabow,

Garrett & Dunner, L.L.P.

Arrowhead Pharmaceuticals, Inc

Patent Term Application

REDEMPLO (plozasiran)

Patent No. 11,214,801

OPEN